There are currently 232 clinical trials in Baton Rouge, Louisiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Pennington Biomedical Research Center, Mary Bird Perkins Cancer Center, LSU Health Baton Rouge-North Clinic and Louisiana Hematology Oncology Associates LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)
NCT04956549
Recruiting
The RAATE-MCI proposal is designed to determine the effects of physical activity on risk factors for Alzheimer's Disease in older African American adults. The study will compare a physical activity program to an active control group. RAATE-MCI is a 52-week randomized controlled trial. 144 African American adults aged 60 and older will be recruited.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/12/2025
Locations: Pennington Biomedical Research, Baton Rouge, Louisiana
Conditions: Dementia of Alzheimer Type
Register for Updates
Treatment to Regress to Normoglycemia in Women with a Recent History of GDM
NCT04873050
Recruiting
The purpose of the study is to determine the efficacy of semaglutide 1mg (Ozempic®) to aid recently postpartum women with dysglycemia and a history of GDM to regress to normoglycemia; thereby filling a gap in efficacious pharmacologic intervention options for clinicians to support postpartum diabetes recovery and reduce future risk of T2DM in young women.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
03/10/2025
Locations: Woman's Hospital, Baton Rouge, Louisiana
Conditions: Pre Diabetes, Postpartum Disorder
Register for Updates
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
NCT06024746
Recruiting
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: CON-10030 Baton Rouge, LA Investigational Site, Baton Rouge, Louisiana
Conditions: Heart Failure
Register for Updates
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT04956640
Recruiting
The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana
Conditions: Carcinoma, Non-Small-Cell Lung, Endometrial Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Biliary Tract Neoplasms, Colorectal Neoplasms
Register for Updates
Sickle Cell Clinical Research and Intervention Program
NCT02098863
Recruiting
Despite the important work of previous sickle cell disease (SCD) cohort studies, there remain many understudied areas that require investigation. An important knowledge deficit is the slow but progressive process of chronic end-organ dysfunction. The majority of organ dysfunction becomes apparent in the young adult years, but comprehensive assessment of adults and understanding of predictors of adulthood organ dysfunction are insufficient. Similarly, the role of disease-modifying therapies, such... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/25/2025
Locations: Our Lady of the Lake Regional Medical Center, Baton Rouge, Louisiana
Conditions: Sickle Cell Disease
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Our Lady of the Lake Physician Group, Baton Rouge, Louisiana
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
The Effects of Metabolic & Bariatric Surgery on Lipid Metabolism, Myeloid-Derived Suppressor Cells, and Cancer Cell Biology
NCT06059651
Recruiting
This study aims to determine the relationship between lipid kinetics changes and blood immunosuppressive cells by metabolic surgery in two patient cohorts.
Gender:
FEMALE
Ages:
Between 35 years and 60 years
Trial Updated:
02/13/2025
Locations: Pennington Biomedical Resarch Center, Baton Rouge, Louisiana
Conditions: Obesity
Register for Updates
The Intestinal Microbiome in Triple Negative Breast Cancer Treated with Immunotherapy
NCT06318507
Recruiting
This study will determine how the intestinal microbiome differs between patients with obesity and early triple-negative breast cancer who achieve a pathologic complete response from preoperative anti-PD-1 immunotherapy (pembrolizumab) versus patients who do not.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Breast Neoplasms
Register for Updates
Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
NCT03755804
Recruiting
This is a phase II study using risk and response-adapted therapy for low, intermediate and high risk classical Hodgkin lymphoma. Chemotherapy regimens will be based on risk group assignment. Low-risk and intermediate- risk patients will be treated with bendamustine, etoposide, Adriamycin® (doxorubicin), bleomycin, Oncovin® (vincristine), vinblastine, and prednisone (BEABOVP) chemotherapy. High-risk patients will receive Adcetris® (brentuximab vedotin), etoposide, prednisone and Adriamycin® (doxo... Read More
Gender:
ALL
Ages:
25 years and below
Trial Updated:
02/06/2025
Locations: St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana
Conditions: Hodgkin Lymphoma
Register for Updates
Testing the Adipose Expandability Hypothesis in Vivo During Overfeeding
NCT04583514
Recruiting
Adipose, or fat, tissue is a plastic organ that retains the ability to expand and store excess calories during positive energy balance in humans. The capacity of subcutaneous (subQ) adipose tissue to expand and remodel is an important determinant of obesity-related health complications, and impaired expansion of subQ fat tissue is thought to contribute to the risk of diseases such as the Metabolic Syndrome (MetS) and type 2 diabetes mellitus (T2D). The objectives of the study are to evaluate the... Read More
Gender:
ALL
Ages:
Between 18 years and 42 years
Trial Updated:
02/03/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Overweight and Obesity, Metabolic Syndrome
Register for Updates
Athlete Needs Assessment & Focus Groups
NCT06213350
Recruiting
The overall objective of this study is to investigate various physical and mental health needs of collegiate athletes and how they differ in and out of sport. Researchers aim to identify facets of support that athletes may need when transitioning out of sport. To achieve this objective, the study is broken down into two specific parts: 1) an online, anonymous survey assessing 200 athletes to evaluate support needed both during and post sport, quantitatively; and 2) focus groups with 50 athletes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Athlete Support
Register for Updates
Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU)
NCT06162728
Recruiting
This trial will be performed as a three-part dose escalating clinical trial where Parts 1 is open label and Parts 2 and 3 are randomized, double-blinded, and placebo-controlled. The trial is intended to determine the safety and tolerability and assess the preliminary efficacy of briquilimab in adult participants with chronic spontaneous urticaria (CSU), who remain symptomatic despite treatment with H1 antihistamines and omalizumab. Additionally, pharmacokinetic (PK) properties of briquilimab, a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: Site 125, Baton Rouge, Louisiana
Conditions: Chronic Spontaneous Urticaria
Register for Updates